MK-6482 as a potential treatment for von Hippel-Lindau disease-associated clear cell renal cell carcinoma

References

• Gossage L, Eisen T, Maher ER. VHL, the story of a tumour suppressor gene. Nat Rev Cancer. 2015;15(1):55–64.
   PubMed Web of Science ®Google Scholar
• Glenn GM, Daniel LN, Choyke P, et al. Von Hippel-Lindau (VHL) disease: distinct phenotypes suggest more than one mutant allele at the VHL locus. Hum Genet. 1991;87(2):207–210.
   PubMed Web of Science ®Google Scholar
• Neumann HP, Wiestler OD. Clustering of features of von Hippel-Lindau syndrome: evidence for a complex genetic locus. Lancet. 1991;337(8749):1052–1054.
   PubMed Web of Science ®Google Scholar
• Chen F, Kishida T, Yao M, et al. Germline mutations in the von Hippel-Lindau disease tumor suppressor gene: correlations with phenotype. Hum Mutat. 1995;5(1):66–75.
   PubMed Web of Science ®Google Scholar
• Hoffman MA, Ohh M, Yang H, et al. von Hippel-Lindau protein mutants linked to type 2C VHL disease preserve the ability to downregulate HIF. Hum Mol Genet. 2001;10(10):1019–1027.
   PubMed Web of Science ®Google Scholar
• Crespigio J, Berbel LCL, Dias MA, et al. Von Hippel–Lindau disease: a single gene, several hereditary tumors. J Endocrinol Invest. 2018;41(1):21–31.
   PubMed Web of Science ®Google Scholar
• Lonser RR, Glenn GM, Walther M, et al. von Hippel-Lindau disease. Lancet. 2003;296(9374):2059–2067.
   Google Scholar
• Pavlovich CP, Walther M, Choyke PL, et al. Percutaneous radio frequency ablation of small renal tumors: initial results. J Urol. 2002;167(1):10–15.
   PubMed Web of Science ®Google Scholar
• Walther MM, Choyke PL, Glenn G, et al. Renal cancer in families with hereditary renal cancer: prospective analysis of a tumor size threshold for renal parenchymal sparing surgery. J Urol. 1999;14(5):1475–1479.
   Google Scholar
• Chahoud J, McGettigan M, Parikh N, et al. Evaluation, diagnosis and surveillance of renal masses in the setting of VHL disease. World J Urol. 2020. 10.1007/s00345-020-03441-3.
   PubMed Web of Science ®Google Scholar
• Chauveau D, Duvic C, Chretien Y, et al. Renal involvement in von Hippel-Lindau disease. Kidney Int. 1996;50(3):944–951.
   PubMed Web of Science ®Google Scholar
• Goldfarb DA, Neumann HP, Penn I, et al. Results of renal transplantation in patients with renal cell carcinoma and von Hippel-Lindau disease. Transplantation. 1997;64(12):1726–1729.
   PubMed Web of Science ®Google Scholar
• Chittiboina P, Lonser RR. Von Hippel-Lindau disease. Handb Clin Neurol. 2015;132:139–156.
   PubMedGoogle Scholar
• Ciccarese C, Brunelli M, Montironi R, et al. The prospect of precision therapy for renal cell carcinoma. Cancer Treat Rev. 2016;49:37–44.
   PubMed Web of Science ®Google Scholar
• Santoni M, Massari F, Di Nunno V, et al. Immunotherapy in renal cell carcinoma: latest evidence and clinical implications. Drugs in Context. 2018;7:212528.
   PubMedGoogle Scholar
• Jonasch E, McCutcheon IE, Waguespack SG, et al. Pilot trial of sunitinib therapy in patients with von Hippel–Lindau disease. Ann Oncol. 2011;22(12):2661–2666.
   PubMed Web of Science ®Google Scholar
• Jonasch E, McCutcheon IE, Gombos DS, et al. Pazopanib in patients with von Hippel-Lindau disease: a single-arm, single-centre, phase 2 trial. Lancet Oncol. 2018;19(10):1351–1359.
   PubMed Web of Science ®Google Scholar
• Latif F, Tory K, Gnarra J, et al. Identification of the von Hippel-Lindau disease tumor suppressor gene. Science. 1993;260(5112):1317–1320.
   PubMed Web of Science ®Google Scholar
• Crossey PA, Foster K, Richards FM, et al. Molecular genetic investigations of the mechanism of tumourigenesis in von Hippel-Lindau disease: analysis of allele loss in VHL tumours. Hum Genet. 1994;93(1):53–58.
   PubMed Web of Science ®Google Scholar
• Iliopoulos O, Ohh M, Kaelin WG Jr. pVHL19 is a biologically active product of the von Hippel-Lindau gene arising from internal translation initiation. Proceedings of the National Academy of Sciences of the United States of America 1998; 95: 11661–11666.
   Google Scholar
• Schoenfeld A, Davidowitz EJ, Burk RD A second major native von Hippel-Lindau gene product, initiated from an internal translation start site, functions as a tumor suppressor. Proceedings of the National Academy of Sciences of the United States of America 1998; 95: 8817–8822.
   Google Scholar
• Blankenship C, Naglich JG, Whaley JM, et al. Alternate choice of initiation codon produces a biologically active product of the von Hippel Lindau gene with tumor suppressor activity. Oncogene. 1999;18(8):1529–1535.
   PubMed Web of Science ®Google Scholar
• Duan DR, Pause A, Burgess WH, et al. Inhibition of transcription elongation by the VHL tumor suppressor protein. Science. 1995;269(5229):1402–1406.
   PubMed Web of Science ®Google Scholar
• Kibel A, Iliopoulos O, DeCaprio JA, et al. Binding of the von Hippel-Lindau tumor suppressor protein to Elongin B and C. Science. 1995;269(5229):1444–1446.
   PubMed Web of Science ®Google Scholar
• Kishida T, Stackhouse TM, Chen F, et al. Cellular proteins that bind the von Hippel-Lindau disease gene product: mapping of binding domains and the effect of missense mutations. Cancer Res. 1995;55(20):4544–4548.
   PubMed Web of Science ®Google Scholar
• Lonergan KM, Iliopoulos O, Ohh M, et al. Regulation of hypoxia-inducible mRNAs by the von Hippel-Lindau tumor suppressor protein requires binding to complexes containing elongins B/C and Cul2. Mol Cell Biol. 1998;18(2):732–741.
   PubMed Web of Science ®Google Scholar
• Kamura T, Koepp DM, Conrad MN, et al. Rbx1, a component of the VHL tumor suppressor complex and SCF ubiquitin ligase. Science. 1999;284(5414):657–661.
   PubMed Web of Science ®Google Scholar
• Pause A, Lee S, Worrell RA, et al. The von Hippel-Lindau tumor-suppressor gene product forms a stable complex with human CUL-2, a member of the Cdc53 family of proteins. Proc Natl Acad Sci U S A. 1997;94(6):2156–2161.
   PubMed Web of Science ®Google Scholar
• Schoenfeld AR, Davidowitz EJ, Burk RD. Elongin BC complex prevents degradation of von Hippel-Lindau tumor suppressor gene products. Proc Natl Acad Sci U S A. 2000;97(15):8507–8512.
   PubMed Web of Science ®Google Scholar
• Maxwell PH, Wiesener MS, Chang GW, et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature. 1999;399(6733):271–275.
   PubMed Web of Science ®Google Scholar
• Ohh M, Park CW, Ivan M, et al. Ubiquitination of hypoxia-inducible factor requires direct binding to the β-domain of the von Hippel–Lindau protein. Nat Cell Biol. 2000;2(7):423–427.
   PubMed Web of Science ®Google Scholar
• Hon WC, Wilson MI, Harlos K, et al. Structural basis for the recognition of hydroxyproline in HIF-1α by pVHL. Nature. 2002;417(6892):975–978.
   PubMed Web of Science ®Google Scholar
• Min JH, Yang H, Ivan M, et al. Structure of an HIF-1alpha -pVHL complex: hydroxyproline recognition in signaling. Science. 2002;296(5574):1886–1889.
   PubMed Web of Science ®Google Scholar
• Bruick RK, McKnight SL. A conserved family of prolyl-4-hydroxylases that modify HIF. Science. 2001;294(5545):1337–1340.
   PubMed Web of Science ®Google Scholar
• Ivan M, Kondo K, Yang H, et al. HIFalpha Targeted for VHL-Mediated Destruction by Proline Hydroxylation: implications for O2 Sensing. Science. 2001;292(5516):464–468.
   PubMed Web of Science ®Google Scholar
• Jaakkola P, Mole DR, Tian YM, et al. Targeting of HIF-alpha to the von Hippel-Lindau Ubiquitylation Complex by O2-Regulated Prolyl Hydroxylation. Science. 2001;292(5516):468–472.
   PubMed Web of Science ®Google Scholar
• Yu F, White SB, Zhao Q, et al. HIF-1 binding to VHL is regulated by stimulus-sensitive proline hydroxylation. Proc Natl Acad Sci U S A. 2001;98(17):9630–9635.
   PubMed Web of Science ®Google Scholar
• Knauth K, Bex C, Jemth P, et al. Renal cell carcinoma risk in type 2 von Hippel–Lindau disease correlates with defects in pVHL stability and HIF-1α interactions. Oncogene. 2006;25(3):370–377.
   PubMed Web of Science ®Google Scholar
• Clifford SC, Cockman ME, Smallwood AC, et al. Contrasting effects on HIF-1alpha regulation by disease-causing pVHL mutations correlate with patterns of tumourigenesis in von Hippel-Lindau disease. Hum Mol Genet. 2001;10(10):1029–1038.
   PubMed Web of Science ®Google Scholar
• Li L, Zhang L, Zhang X, et al. Hypoxia-inducible factor linked to differential kidney cancer risk seen with type 2A and type 2B VHL mutations. Mol Cell Biol. 2007;27(15):5381–5392.
   PubMed Web of Science ®Google Scholar
• Semenza GL. Hypoxia-inducible factors: mediators of cancer progression and targets for cancer therapy. Trends Pharmacol Sci. 2012;33(4):207–214.
   PubMed Web of Science ®Google Scholar
• Wang GL, Jiang BH, Rue EA, et al. Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc Natl Acad Sci U S A. 1995;92(12):5510–5514.
   PubMed Web of Science ®Google Scholar
• Xia X, Lemieux ME, Li W, et al. Integrative analysis of HIF binding and transactivation reveals its role in maintaining histone methylation homeostasis. Proc Natl Acad Sci U S A. 2009;106(11):4260–4265.
   PubMed Web of Science ®Google Scholar
• Schodel J, Oikonomopoulos S, Ragoussis J, et al. High-resolution genome-wide mapping of HIF-binding sites by ChIP-seq. Blood. 2011;117(23):e207–217.
   PubMed Web of Science ®Google Scholar
• Gnarra JR, Zhou S, Merrill MJ et al. Post-transcriptional regulation of vascular endothelial growth factor mRNA by the product of the VHL tumor suppressor gene. Proceedings of the National Academy of Sciences of the United States of America 1996; 93: 10589–10594.
   Google Scholar
• Iliopoulos O, Levy AP, Jiang C, et al. Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein. Proc Natl Acad Sci U S A. 1996;93(20):10595–10599.
   PubMed Web of Science ®Google Scholar
• Hu CJ, Wang LY, Chodosh LA, et al. Differential Roles of Hypoxia-Inducible Factor 1α (HIF-1α) and HIF-2α in Hypoxic Gene Regulation. Mol Cell Biol. 2003;23(24):9361–9374.
   PubMed Web of Science ®Google Scholar
• Zatyka M, Da Silva NF, Clifford SC, et al. Identification of cyclin D1 and other novel targets for the von Hippel-Lindau tumor suppressor gene by expression array analysis and investigation of cyclin D1 genotype as a modifier in von Hippel-Lindau disease. Cancer Res. 2002;62(13):3803–3811.
   PubMed Web of Science ®Google Scholar
• Carroll VA, Ashcroft M. Role of Hypoxia-Inducible Factor (HIF)-1α versus HIF-2α in the Regulation of HIF target genes in response to Hypoxia, Insulin-Like Growth Factor-I, or Loss of von Hippel-Lindau Function: implications for targeting the HIF Pathway. Cancer Res. 2006;66(12):6264–6270.
   PubMed Web of Science ®Google Scholar
• Kim WY, Safran M, Buckley MR, et al. Failure to prolyl hydroxylate hypoxia-inducible factor α phenocopies VHL inactivation in vivo. EMBO J. 2006;25(19):4650–4662.
   PubMed Web of Science ®Google Scholar
• Rankin EB, Biju MP, Liu Q, et al. Hypoxia-inducible factor–2 (HIF-2) regulates hepatic erythropoietin in vivo. J Clin Invest. 2007;117(4):1068–1077.
   PubMed Web of Science ®Google Scholar
• Rankin EB, Higgins DF, Walisser JA, et al. Inactivation of the arylhydrocarbon receptor nuclear translocator (Arnt) suppresses von Hippel-Lindau disease-associated vascular tumors in mice. Mol Cell Biol. 2005;25(8):3163–3172.
   PubMed Web of Science ®Google Scholar
• Rankin EB, Rha J, Selak MA, et al. Hypoxia-inducible factor 2 regulates hepatic lipid metabolism. Mol Cell Biol. 2009;29(16):4527–4538.
   PubMed Web of Science ®Google Scholar
• Rankin EB, Rha J, Unger TL, et al. Hypoxia-inducible factor-2 regulates vascular tumorigenesis in mice. Oncogene. 2008;27(40):5354–5358.
   PubMed Web of Science ®Google Scholar
• Kondo K, Kim WY, Lechpammer M, et al. Inhibition of HIF2α Is Sufficient to Suppress pVHL-Defective Tumor Growth. PLoS Biol. 2003;1(3):E83.
   PubMed Web of Science ®Google Scholar
• Zimmer M, Doucette D, Siddiqui N, et al. Inhibition of hypoxia-inducible factor is sufficient for growth suppression of VHL-/- tumors. Mol Cancer Res. 2004;2(2):89–95.
   PubMed Web of Science ®Google Scholar
• Kondo K, Klco J, Nakamura E, et al. Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein. Cancer Cell. 2002;1(3):237–246.
   PubMed Web of Science ®Google Scholar
• Raval RR, Lau KW, Tran MG, et al. Contrasting properties of hypoxia-inducible factor 1 (HIF-1) and HIF-2 in von Hippel-Lindau-associated renal cell carcinoma. Mol Cell Biol. 2005;25(13):5675–5686.
   PubMed Web of Science ®Google Scholar
• Gordan JD, Lal P, Dondeti VR, et al. HIF-α Effects on c-Myc Distinguish Two Subtypes of Sporadic VHL-Deficient Clear Cell Renal Carcinoma. Cancer Cell. 2008;14(6):435–446.
   PubMed Web of Science ®Google Scholar
• Shen C, Beroukhim R, Schumacher SE, et al. Genetic and Functional Studies Implicate HIF1 α as a 14q Kidney Cancer Suppressor Gene. Cancer Discov. 2011;1(3):222–235.
   PubMed Web of Science ®Google Scholar
• Maranchie JK, Vasselli JR, Riss J, et al. The contribution of VHL substrate binding and HIF1-α to the phenotype of VHL loss in renal cell carcinoma. Cancer Cell. 2002;1(3):247–255.
   PubMed Web of Science ®Google Scholar
• Mandriota SJ, Turner KJ, Davies DR, et al. HIF activation identifies early lesions in VHL kidneys: evidence for site-specific tumor suppressor function in the nephron. Cancer Cell. 2002;1(5):459–468.
   PubMed Web of Science ®Google Scholar
• Pollard PJ, El-Bahrawy M, Poulsom R, et al. Expression of HIF-1α, HIF-2α (EPAS1), and Their Target Genes in Paraganglioma and Pheochromocytoma with VHL and SDH Mutations. J Clin Endocrinol Metab. 2006;18(11):4593–4598.
   Google Scholar
• Massari ME, Murre C. Helix-loop-helix proteins: regulators of transcription in eucaryotic organisms. Mol Cell Biol. 2000;20(2):429–440.
   PubMed Web of Science ®Google Scholar
• Pongratz I, Antonsson C, Whitelaw ML, et al. Role of the PAS domain in regulation of dimerization and DNA binding specificity of the dioxin receptor. Mol Cell Biol. 1998;18(7):4079–4088.
   PubMed Web of Science ®Google Scholar
• Jiang BH, Rue E, Wang GL, et al. Dimerization, DNA binding, and transactivation properties of hypoxia-inducible factor 1. J Biol Chem. 1996;271(30):17771–17778.
   PubMed Web of Science ®Google Scholar
• Erbel PJ, Card PB, Karakuzu O, et al. Structural basis for PAS domain heterodimerization in the basic helix-loop-helix-PAS transcription factor hypoxia-inducible factor. Proc Natl Acad Sci U S A. 2003;100(26):15504–15509.
   PubMed Web of Science ®Google Scholar
• Scheuermann TH, Tomchick DR, Machius M, et al. Artificial ligand binding within the HIF2 PAS-B domain of the HIF2 transcription factor. Proc Natl Acad Sci U S A. 2009;106(2):450–455.
   PubMed Web of Science ®Google Scholar
• Scheuermann TH, Li Q, Ma HW, et al. Allosteric inhibition of hypoxia inducible factor-2 with small molecules. Nat Chem Biol. 2013;2(4):271–276.
   Google Scholar
• Rogers JL, Bayeh L, Scheuermann TH, et al. Development of Inhibitors of the PAS-B Domain of the HIF-2α Transcription Factor. J Med Chem. 2013;56(4):1739–1747.
   PubMed Web of Science ®Google Scholar
• Scheuermann TH, Stroud D, Sleet CE, et al. Isoform-Selective and Stereoselective Inhibition of Hypoxia Inducible Factor-2. J Med Chem. 2015;58(15):5930–5941.
   PubMed Web of Science ®Google Scholar
• Wallace EM, Rizzi JP, Han G, et al. A Small-Molecule Antagonist of HIF2α Is Efficacious in Preclinical Models of Renal Cell Carcinoma. Cancer Res. 2016;76(18):5491–5500.
   PubMed Web of Science ®Google Scholar
• Wehn PM, Rizzi JP, Dixon DD, et al. Design and Activity of Specific Hypoxia-Inducible Factor-2α (HIF-2α) Inhibitors for the Treatment of Clear Cell Renal Cell Carcinoma: discovery of Clinical Candidate (S)-3-((2,2-Difluoro-1-hydroxy-7-(methylsulfonyl)-2,3-dihydro-1 H-inden-4-yl)oxy)-5-fluorobenzonitrile (PT2385). J Med Chem. 2018;62(21):9691–9721.
   Google Scholar
• Chen W, Hill H, Christie A, et al. Targeting renal cell carcinoma with a HIF-2 antagonist. Nature. 2016;539(7627):112–117.
   PubMed Web of Science ®Google Scholar
• Cho H, Du X, Rizzi JP, et al. On-target efficacy of a HIF-2α antagonist in preclinical kidney cancer models. Nature. 2016;539(7627):107–111.
   PubMed Web of Science ®Google Scholar
• Courtney KD, Infante JR, Lam ET, et al. Phase I Dose-Escalation Trial of PT2385, a First-in-Class Hypoxia-Inducible Factor-2α Antagonist in Patients With Previously Treated Advanced Clear Cell Renal Cell Carcinoma. J Clin Oncol. 2018;36(9):867–874.
   PubMed Web of Science ®Google Scholar
• Xu R, Wang K, Rizzi JP, et al. 3-[(1S,2S,3R)-2,3-Difluoro-1-hydroxy-7-methylsulfonylindan-4-yl]oxy-5-fluorobenzonitrile (PT2977), a Hypoxia-Inducible Factor 2α (HIF-2α) Inhibitor for the Treatment of Clear Cell Renal Cell Carcinoma. J Med Chem. 2019;62(15):6876–6893.
   PubMed Web of Science ®Google Scholar
• Papadopoulos KP, Jonasch E, Zojwalla NJ, et al. A first-in-human phase 1 dose-escalation trial of the oral HIF-2a inhibitor PT2977 in patients with advanced solid tumors. Journal of Clinical Oncology. 2018;36(15_suppl):2508.
   Google Scholar
• Jonasch E, Klaassen Z A First-in-Human Phase 1/2 Trial of the Oral HIF-2a Inhibitor PT2977 in Patients with Advanced RCC (Clinical trial identification: NCT02974738). In. ESMO 2019.
   Google Scholar
• Choueiri TK, Plimack ER, Bauer TM, et al., Phase I/II study of the oral HIF-2 α inhibitor MK-6482 in patients with advanced clear cell renal cell carcinoma (RCC). Journal of Clinical Oncology. 38(6_suppl): 611. 2020.
   Google Scholar
• Bauer TM, Choueiri TK, Papadopoulos KP, et al. The oral HIF-2 α inhibitor MK-6482 in patients with advanced clear cell renal cell carcinoma (RCC): updated follow-up of a phase I/II study. Journal of Clinical Oncology 39, no. 6_suppl. 2021:273–273.
   Google Scholar
• Jonasch E, Donskov F, Iliopoulos O, et al., Phase II study of the oral HIF-2α inhibitor MK-6482 for Von Hippel-Lindau disease–associated renal cell carcinoma. Journal of Clinical Oncology. 38(15_suppl): 5003. 2020.
   Web of Science ®Google Scholar
• Srinivasan R, Donskov F, Iliopoulos O, et al. LBA26 Phase II study of the oral HIF-2α inhibitor MK-6482 for Von Hippel-Lindau (VHL) disease-associated clear cell renal cell carcinoma (ccRCC): update on RCC and non-RCC disease. Ann Oncol. 2020;31:S1158.
   Web of Science ®Google Scholar
• Iliopoulos O, Jonasch E, Donskov F, et al. Phase II study of the oral hypoxia-inducible factor 2α (HIF-2α) inhibitor MK-6482 for Von Hippel-Lindau (VHL) disease-associated clear cell renal cell carcinoma (ccRCC). Journal of Clinical Oncology. 2021;39(6_suppl):333.
   Web of Science ®Google Scholar